Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Chronic Heart Failure

Free Subscription Articles published in J Cardiovasc Pharmacol Retrieve available abstracts of 67 articles: HTML format

Single Articles

September 2026
1. LOTAN D, Elad B, Lee C, Richter I, et al
   The Novelty of Anticoagulation in LVAD Therapy: Current Practice, the Role of Direct Oral Anticoagulants, and Future Directions.
   J Cardiovasc Pharmacol. 2026;88:190-197.
   PubMed     Abstract available
   
   
   August 2026
2. BOGIN V, Weir MR
   Eplerenone Revisited: A Balanced Reappraisal of Its Role in Hypertension, Heart Failure, and Cardiorenal Disease.
   J Cardiovasc Pharmacol. 2026 Aug 19. doi: 10.1097/FJC.0000000000001875.
   PubMed     Abstract available
   
   
   July 2026
3. KELLY J, Mezzaroma E, Roscioni A, McSkimming C, et al
   INTERLEUKIN-1 RECEPTOR ANTAGONIST LEVELS IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TREATED WITH ANAKINRA.
   J Cardiovasc Pharmacol. 2026 Jul 1. doi: 10.1097/FJC.0000000000001849.
   PubMed     Abstract available
   
   
   June 2026
4. LOEB SA, Tharp DL, Zawieja SD, Pal S, et al
   Pitfalls of therapies targeting the nitric oxide signaling pathway in heart failure with preserved ejection fraction.
   J Cardiovasc Pharmacol. 2026 Jun 22. doi: 10.1097/FJC.0000000000001844.
   PubMed     Abstract available
   
   
   April 2026
5. ABDELHAMID A, Arabi A, Rajha H, Tluli O, et al
   Efficacy and Safety of the beta3-Adrenergic Agonist Mirabegron in Patients with Heart Failure: An Updated Systematic Review and Meta-Analysis.
   J Cardiovasc Pharmacol. 2026 Apr 8. doi: 10.1097/FJC.0000000000001821.
   PubMed     Abstract available
   
   
   
6. WANG YQ, Deng QY, Zhang ZZ, Wang GL, et al
   Short-Term Effect of Levosimendan in Acute Right Heart Failure Caused by Pulmonary Hypertension: A Pilot Study.
   J Cardiovasc Pharmacol. 2026 Apr 8. doi: 10.1097/FJC.0000000000001824.
   PubMed     Abstract available
   
   
   February 2026
7. SARTO G, Simeone B, Sbandi F, Valenti V, et al
   Magnitude of blood pressure reduction in response to levosimendan infusion independently predicts in-hospital mortality in patients with acute heart failure.
   J Cardiovasc Pharmacol. 2026 Feb 23. doi: 10.1097/FJC.0000000000001811.
   PubMed     Abstract available
   
   
   
8. YAO S, Zhang H, Li M, Han S, et al
   Integrating Network Pharmacology and In Vitro 3D Cardiac Organoid Model Validation to Investigate the Action Mechanism of Shenfu Xiangshao Decoction on Heart Failure.
   J Cardiovasc Pharmacol. 2026 Feb 20. doi: 10.1097/FJC.0000000000001802.
   PubMed     Abstract available
   
   
   January 2026
9. SEMENYCHEVA I, Larina S, Zakharova L, Vakolyuk R, et al
   Safety of Repeated Levosimendan Use in Chronic Heart Failure.
   J Cardiovasc Pharmacol. 2026 Jan 22. doi: 10.1097/FJC.0000000000001797.
   PubMed     Abstract available
   
   
   December 2025
10. ELAD B, Lotan D, Richter I, Changhee L, et al
    Effect of Vericiguat on Pulmonary Artery Pressures in Heart Failure Patients: Real-World Insights from Pressure Sensor Monitoring.
    J Cardiovasc Pharmacol. 2025 Dec 11. doi: 10.1097/FJC.0000000000001761.
    PubMed     Abstract available
    
    
    
11. BERNARDI M, Golino M, Spadafora L, Sarto G, et al
    Current Challenges for the Diagnosis of HFpEF and Possible Simplification of the Diagnostic Approach.
    J Cardiovasc Pharmacol. 2025;86:522-534.
    PubMed     Abstract available
    
    
    
12. SONG C, Tang Q, Liu L, Zhou G, et al
    CDK Inhibitor R547 Attenuates Pressure Overload-Induced Cardiac Hypertrophy Through PI3K/AKT and TGF-beta/Smad3 Signaling Pathways.
    J Cardiovasc Pharmacol. 2025;86:557-564.
    PubMed     Abstract available
    
    
    November 2025
13. XIE Y, Huang T, Wang H, Yang J, et al
    Lactylation-Related Gene Signature and Immune Infiltration Crosstalk in Heart Failure: Insights from Bulk and Single-Cell Transcriptomics.
    J Cardiovasc Pharmacol. 2025 Nov 18. doi: 10.1097/FJC.0000000000001775.
    PubMed     Abstract available
    
    
    October 2025
14. ACOSTA C, Anderson HD, Anderson CM
    Disparate mechanical and functional properties of spontaneously hypertensive rat (SHR) and spontaneously hypertensive heart failure (SHHF) rat penetrating arterioles.
    J Cardiovasc Pharmacol. 2025 Oct 31. doi: 10.1097/FJC.0000000000001770.
    PubMed     Abstract available
    
    
    
15. NILO D, Gualdiero F, Russo V, Zielinska K, et al
    Commentary On the Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials.
    J Cardiovasc Pharmacol. 2025 Oct 10. doi: 10.1097/FJC.0000000000001767.
    PubMed    
    
    
    September 2025
16. HOGWOOD AC, Golino M, Moroni F, Canada JM, et al
    The Effects of Anakinra on Cardiorespiratory Fitness in Heart Failure Stratified by Age in Phase II Clinical Trials.
    J Cardiovasc Pharmacol. 2025 Sep 9. doi: 10.1097/FJC.0000000000001756.
    PubMed     Abstract available
    
    
    August 2025
17. GALLUZZO A, Bertaina M, Vishram-Nielsen JKK, Camilli M, et al
    Current Practices and Perspectives on the Use of Intravenous Vasodilators in Acute Heart Failure: An International Survey.
    J Cardiovasc Pharmacol. 2025 Aug 20. doi: 10.1097/FJC.0000000000001753.
    PubMed     Abstract available
    
    
    
18. WEN S, Liu X, Liu L, Hu Y, et al
    Landscape of Berberine Targets: A Potential Pharmacological Insight for Heart failure Treatment.
    J Cardiovasc Pharmacol. 2025 Aug 20. doi: 10.1097/FJC.0000000000001750.
    PubMed     Abstract available
    
    
    June 2025
19. ABBATE A
    Heart failure with preserved ejection fraction: how far we've come - a brief report from two outstanding educational events.
    J Cardiovasc Pharmacol. 2025 Jun 27. doi: 10.1097/FJC.0000000000001733.
    PubMed    
    
    
    
20. WU Y, Song M, Chen W, Liang F, et al
    miR-132 inhibition improves cardiac remodeling and function in a two-hit mouse model of heart failure with a preserved ejection fraction.
    J Cardiovasc Pharmacol. 2025 Jun 18. doi: 10.1097/FJC.0000000000001729.
    PubMed     Abstract available
    
    
    May 2025
21. ZHANG J, Chen X, Wan C
    Aerobic exercise rehabilitation training alleviates skeletal muscle atrophy caused by heart failure in mice through the SIRT1/PGC-1alpha pathway.
    J Cardiovasc Pharmacol. 2025 May 28. doi: 10.1097/FJC.0000000000001722.
    PubMed     Abstract available
    
    
    
22. YAMASHITA I, Fujisaki T, Romeo FJ, Sueta D, et al
    Comparing the Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors Among Nonolder and Older Patients: A Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2025;85:329-337.
    PubMed     Abstract available
    
    
    April 2025
23. CHEN C, Qin X, Cao Y, Qing L, et al
    Flavin adenine dinucleotide ameliorates pressure overload-induced heart failure by activating the short-chain acyl-CoA dehydrogenase.
    J Cardiovasc Pharmacol. 2025 Apr 8. doi: 10.1097/FJC.0000000000001698.
    PubMed     Abstract available
    
    
    March 2025
24. BIONDI-ZOCCAI G, Galli M, Booz GW
    Finerenone Proves Beneficial for Heart Failure With Preserved Ejection Fraction, Erratum.
    J Cardiovasc Pharmacol. 2025;85:238.
    PubMed    
    
    
    February 2025
25. GALATI G, Germanova O
    Mineralocorticoid receptor antagonists in end-stage renal disease under renal replacement therapies: bridging the gap between cardiovascular and systemic benefit, from heart failure to myocardial infarction.
    J Cardiovasc Pharmacol. 2025 Feb 6. doi: 10.1097/FJC.0000000000001677.
    PubMed    
    
    
    January 2025
26. DIMITRIADIS K, Pitsiori D, Alexiou P, Pyrpyris N, et al
    Modulating Sympathetic Nervous System With the Use of SGLT2 Inhibitors: Where There Is Smoke, There Is Fire?
    J Cardiovasc Pharmacol. 2025;85:12-20.
    PubMed     Abstract available
    
    
    December 2024
27. KEFER E, Gulbis B, Weeks P
    Comparison of Urine Output Response of Intravenous Bumetanide and Furosemide in Acute Decompensated Heart Failure: an observational analysis.
    J Cardiovasc Pharmacol. 2024 Dec 5. doi: 10.1097/FJC.0000000000001658.
    PubMed     Abstract available
    
    
    November 2024
28. DENICOLAI M, Morello M, Golino M, Corna G, et al
    Interleukin-1 Blockade in Patients With ST-Segment Elevation Myocardial Infarction Across the Spectrum of Coronary Artery Disease Complexity.
    J Cardiovasc Pharmacol. 2024 Nov 12. doi: 10.1097/FJC.0000000000001652.
    PubMed     Abstract available
    
    
    September 2024
29. RYUNO Y, Kobayashi JI, Fujimoto Y, Dotare T, et al
    Effect of an Enteral Formula Enriched with omega-3 Fatty Acids, Carnitine, and Vitamin D on Body Weight, Heart Weight, and Blood Biochemical Parameters in a Dahl Rat Heart Failure Model.
    J Cardiovasc Pharmacol. 2024 Sep 26. doi: 10.1097/FJC.0000000000001637.
    PubMed     Abstract available
    
    
    
30. BIONDI-ZOCCAI G, Galli M, Booz GW
    Finerenone Proves Beneficial for Heart Failure with Preserved Ejection Fraction.
    J Cardiovasc Pharmacol. 2024 Sep 26. doi: 10.1097/FJC.0000000000001636.
    PubMed    
    
    
    
31. BIONDI-ZOCCAI G, Frati G, Peruzzi M, Booz GW, et al
    Empagliflozin: Primus Inter Pares Among Sodium-Glucose Cotransporter-2 Inhibitors?
    J Cardiovasc Pharmacol. 2024;84:271-275.
    PubMed     Abstract available
    
    
    
32. HAJIQASEMI M, Ebrahimzade M, Ghelichkhan ZA, Huang X, et al
    Ivabradine Approved and Other Uses in Clinical Practice: A Systematic Review.
    J Cardiovasc Pharmacol. 2024;84:276-288.
    PubMed     Abstract available
    
    
    August 2024
33. HENSON BD, Bale-Neary CA, Mecaskey R, Gbujie O, et al
    SGLT2 Inhibitors, Malnutrition, Cachexia, and Survival in Heart Failure Patients with a History of Anthracycline Treatment.
    J Cardiovasc Pharmacol. 2024 Aug 7. doi: 10.1097/FJC.0000000000001620.
    PubMed     Abstract available
    
    
    
34. GIBSON CM, Beard MM, Escano AK, Good BL, et al
    Metolazone vs chlorothiazide in acute heart failure patients with diuretic resistance and renal dysfunction: a retrospective cohort study.
    J Cardiovasc Pharmacol. 2024 Aug 7. doi: 10.1097/FJC.0000000000001623.
    PubMed     Abstract available
    
    
    July 2024
35. LINGYAN Z, Zijia H, Ya Z, Ying Z, et al
    Cardiovascular outcomes of SGLT-2 Inhibitors Across BMI Spectrum in Heart Failure Patients: An Updated Systematic Review and Meta-Analysis.
    J Cardiovasc Pharmacol. 2024 Jul 8. doi: 10.1097/FJC.0000000000001610.
    PubMed     Abstract available
    
    
    
36. ZHANG X, Sun G, Li Z, Gao W, et al
    Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Acute Myocardial Infarction With or Without Type 2 Diabetes: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2024;84:18-25.
    PubMed     Abstract available
    
    
    
37. LIU TH, Hsieh RJ, Chen HH, Kuo TJ, et al
    Propranolol Alleviates Cardiac Injury After Acute Catecholamine Infusion Through p38-MAPK Pathways.
    J Cardiovasc Pharmacol. 2024;84:110-117.
    PubMed     Abstract available
    
    
    May 2024
38. HOU B, Yu D, Bai H, Du X, et al
    Research progress of miRNA in heart failure: prediction and treatment.
    J Cardiovasc Pharmacol. 2024 May 3. doi: 10.1097/FJC.0000000000001588.
    PubMed     Abstract available
    
    
    April 2024
39. BARBIERO R, Pennella B, Bonaventura A
    The long-standing search for albumin placement in acute heart failure.
    J Cardiovasc Pharmacol. 2024 Apr 24. doi: 10.1097/FJC.0000000000001580.
    PubMed    
    
    
    
40. KAKZANOV Y, Sevilya Z, Goldman A, Cipok M, et al
    The Effect of SGLT2 Inhibitor Therapy on Endothelial Progenitor Cell Function in Patients with Heart Failure.
    J Cardiovasc Pharmacol. 2024 Apr 24. doi: 10.1097/FJC.0000000000001581.
    PubMed     Abstract available
    
    
    
41. POLLESELLO P
    Repetitive treatments with inotropes in advanced heart failure.
    J Cardiovasc Pharmacol. 2024 Apr 2. doi: 10.1097/FJC.0000000000001569.
    PubMed    
    
    
    
42. 
    The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Erratum.
    J Cardiovasc Pharmacol. 2024;83:359.
    PubMed    
    
    
    March 2024
43. ZHANG X, Wang Z, Zhang L, Zhao X, et al
    Comparative effectiveness and safety of intermittent, repeated or continuous use of levosimendan, milrinone, or dobutamine in patients with advanced heart failure: a network and single-arm meta-analysis.
    J Cardiovasc Pharmacol. 2024 Mar 25. doi: 10.1097/FJC.0000000000001561.
    PubMed     Abstract available
    
    
    
44. ZOHORI BAHRAMI HS, Hasselbalch RB, Soholm H, Thomsen JH, et al
    First-in-man trial of beta3-adrenoceptor agonist treatment in chronic heart failure - impact on diastolic function.
    J Cardiovasc Pharmacol. 2024 Mar 5. doi: 10.1097/FJC.0000000000001545.
    PubMed     Abstract available
    
    
    January 2024
45. HUANG Y, Zhou H, Fang C, Ma L, et al
    Cost-Effectiveness of New Quadruple Therapy Compared With Standard Treatment for Patients With Heart Failure in China.
    J Cardiovasc Pharmacol. 2024;83:86-92.
    PubMed     Abstract available
    
    
    December 2023
46. SCOMA CB, Lee DH, Money D, Eichelberger G, et al
    The Impact of Midodrine On Guideline-Directed Medical Therapy in Patients Admitted with Systolic Heart Failure.
    J Cardiovasc Pharmacol. 2023 Dec 21. doi: 10.1097/FJC.0000000000001532.
    PubMed     Abstract available
    
    
    November 2023
47. SILVETTI S, Pollesello P, Belletti A
    Repeated levosimendan infusions in the management of advanced heart failure: review of the evidence and meta-analysis of the effect on mortality.
    J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001506.
    PubMed     Abstract available
    
    
    
48. SUN Q, Cui W, Zhang X, Tian Y, et al
    A Systematic Review and Meta-analysis of Renin-angiotensin Inhibitors and Angiotensin Receptor Neprilysin Inhibitors in Preventing Recurrence after Atrial Fibrillation Ablation.
    J Cardiovasc Pharmacol. 2023 Nov 22. doi: 10.1097/FJC.0000000000001517.
    PubMed     Abstract available
    
    
    
49. LAI M, Lam JC, Radosevich JJ, Patanwala AE, et al
    Levels of Albumin and Impact on Loop Diuretic and Albumin Co-administration in Heart Failure (LILAC-HF).
    J Cardiovasc Pharmacol. 2023 Nov 17. doi: 10.1097/FJC.0000000000001513.
    PubMed     Abstract available
    
    
    
50. KOMMU S
    The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    J Cardiovasc Pharmacol. 2023 Nov 15. doi: 10.1097/FJC.0000000000001511.
    PubMed     Abstract available
    
    
    
51. ZHANG X, Wang N, Fu P, An Y, et al
    Dapagliflozin Attenuates Heart Failure With Preserved Ejection Fraction Remodeling and Dysfunction by Elevating beta-Hydroxybutyrate-activated Citrate Synthase.
    J Cardiovasc Pharmacol. 2023;82:375-388.
    PubMed     Abstract available
    
    
    October 2023
52. CANTRELL AC, Zeng H, Chen JX
    The therapeutic potential of targeting ferroptosis in the treatment of mitochondrial cardiomyopathies and heart failure.
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001496.
    PubMed     Abstract available
    
    
    
53. JAFREE E, Del Buono MG, Canada JM, Carbone S, et al
    Interleukin-1 Inhibition for the Prevention and Treatment of Heart Failure.
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001497.
    PubMed     Abstract available
    
    
    
54. CAMILLI M, Ballacci F, Giordano F, Minotti G, et al
    Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Patients with Heart Failure in China: a new pillar in our pockets, but at what price?
    J Cardiovasc Pharmacol. 2023 Oct 10. doi: 10.1097/FJC.0000000000001498.
    PubMed     Abstract available
    
    
    September 2023
55. BUONPANE A, Biondi-Zoccai G, Versaci F
    Molecular insights on ischemic heart failure: from core genes to hearts.
    J Cardiovasc Pharmacol. 2023 Sep 26. doi: 10.1097/FJC.0000000000001486.
    PubMed    
    
    
    
56. LIN L, Zicheng L, Shaohua G
    Post-acute myocardial infarction heart failure core genes and relevant signaling pathways.
    J Cardiovasc Pharmacol. 2023 Sep 6. doi: 10.1097/FJC.0000000000001481.
    PubMed     Abstract available
    
    
    
57. BROCKMOLLER J, Ivanoski S, Hundack L, Blohm JH, et al
    Clinical and hemodynamic improvement in pulmonary hypertension after switching to sacubitril/valsartan in heart failure patients with preserved ejection fraction.
    J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001477.
    PubMed     Abstract available
    
    
    
58. PITT B, Rosenson RS
    Statins in patients with established heart failure: Time for reflection.
    J Cardiovasc Pharmacol. 2023 Sep 1. doi: 10.1097/FJC.0000000000001475.
    PubMed    
    
    
    July 2023
59. PARK S, Chang J, Hong SP, Jin ES, et al
    Impact of Trimetazidine on the Incident Heart Failure Following Coronary Artery Revascularization.
    J Cardiovasc Pharmacol. 2023 Jul 11. doi: 10.1097/FJC.0000000000001453.
    PubMed     Abstract available
    
    
    June 2023
60. HU WS, Lin CL
    Angiotensin receptor-neprilysin inhibitor versus renin-angiotensin system inhibitor for dementia risk in patients with heart failure.
    J Cardiovasc Pharmacol. 2023 Jun 30. doi: 10.1097/FJC.0000000000001451.
    PubMed     Abstract available
    
    
    
61. AHMAD F, Karim A, Khan J, Qaisar R, et al
    Statin therapy induces gut leakage and neuromuscular disjunction in patients with chronic heart failure.
    J Cardiovasc Pharmacol. 2023 Jun 27. doi: 10.1097/FJC.0000000000001445.
    PubMed     Abstract available
    
    
    
62. MANILALL A, Mokotedi L, Gunter S, Le Roux R, et al
    Tumor Necrosis Factor-alpha Mediates Inflammation-induced Early-Stage Left Ventricular Systolic Dysfunction.
    J Cardiovasc Pharmacol. 2023;81:411-422.
    PubMed     Abstract available
    
    
    May 2023
63. AUGUSTIN N, Alvarez C, Kluger J
    The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.
    J Cardiovasc Pharmacol. 2023 May 26. doi: 10.1097/FJC.0000000000001439.
    PubMed     Abstract available
    
    
    April 2023
64. HU WS, Lin CL
    Association of heart failure patients with and without sacubitril-valsartan use with incident cancer risk.
    J Cardiovasc Pharmacol. 2023 Apr 28. doi: 10.1097/FJC.0000000000001433.
    PubMed     Abstract available
    
    
    
65. NAKATANI D, Dohi T, Hikoso S, Tanaka A, et al
    Relationship between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients with Diabetes and Mild Heart Failure: Results from the CANDLE trial.
    J Cardiovasc Pharmacol. 2023 Apr 18. doi: 10.1097/FJC.0000000000001430.
    PubMed     Abstract available
    
    
    March 2023
66. ZHANG H, Huetteman AT, Reyes EA, Appelbaum JS, et al
    Effects of sacubitril-valsartan in Patients with Various Types of Heart Failure: A Meta-Analysis.
    J Cardiovasc Pharmacol. 2023 Mar 31. doi: 10.1097/FJC.0000000000001421.
    PubMed     Abstract available
    
    
    
67. KUANG N, Shu B, Yang F, Li S, et al
    TRAIL or TRAIL-R2 as a predictive biomarker for mortality or cardiovascular events: A systematic review and meta-analysis.
    J Cardiovasc Pharmacol. 2023 Mar 9. doi: 10.1097/FJC.0000000000001415.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum